Researchers at Johns Hopkins University School of Medicine find psilocybin causes substantial and sustained decreases in anxiety and depression in patients with life-threatening cancer.
Researchers at the Johns Hopkins School of Medicine studied the effects of psilocybin on treating anxiety and depression in patients with life-threatening cancer. Fifty-one patients received very low (1 or 3 mg/70 kg) or high dose (22 or 30 mg/70 kg) psilocybin and underwent a 6 month follow up. Patients in the high dose group saw large decreases in depressed mood and anxiety. They also had increases in quality of life, optimism, meaning of life, and a decrease in death anxiety.
Psychedelic Science Review is working to bring cutting-edge science in the field of psychedelics to the public in the most accessible, thorough and accurate way possible. Join our communities on Facebook, Twitter, LinkedIn and Instagram and share our content with your network to help us bring scientifically-backed information about psychedelics to the world.
NEW! Shop the PSR Supporter Store to show your support for psychedelic science.